Research shows that a growing number of yeast species are developing resistance to fluconazole 3
Yeast species are less resistant to miconazole, the
active ingredient in MONISTAT®
4Optimal treatment for non-albicans VVC is not yet established
CDC Guidelines suggest a non-fluconazole azole for 7-14 days first-lines2
The Guidelines also include recommendations for treating VVC in certain populations, including women who are pregnant, diabetic, or immunocompromised.
Add subhead to introduce the more technical resistance data.
In a study looking at MIC90 trends from 1986 – 2007 for 250 C. albicans vaginal isolates3:
- Miconazole: MIC90 unchanged (0.06 μg/mL)
- Percent isolates with MIC90 ≥ 0.5 μg/mL increased from 2% to 9% during this period but since this is a topical agent and vaginal fluid levels exceed 10 μg/mL, resistance is unlikely to be an issue
Evolution and selection of vaginal-colonizing Candida 3
Evolution and selection of vaginal-colonizing Candida Candida species with reduced susceptibility could play a critical early role in the development of antifungal resistance among C. albicans isolates responsible for refractory candidiasis.3
- Fluconazole MIC90: 0.25 μg/mL → 0.5 μg/mL
- Percent isolates with MIC90 ≥ 1 μg/mL and ≥ 2 μg/mL both increased from 3% to 9% over this period
- While not a clinically significant MIC90 increase, the increase in isolates with elevated MIC90 may have clinical relevance given the achievable concentrations of fluconazole in vaginal fluid (maximum 2 μg/mL)